Success Metrics

Clinical Success Rate
78.6%

Based on 22 completed trials

Completion Rate
79%(22/28)
Active Trials
0(0%)
Results Posted
55%(12 trials)
Terminated
6(19%)

Phase Distribution

Ph phase_3
4
13%
Ph phase_4
14
44%
Ph phase_1
4
13%
Ph phase_2
8
25%

Phase Distribution

4

Early Stage

8

Mid Stage

18

Late Stage

Phase Distribution30 total trials
Phase 1Safety & dosage
4(13.3%)
Phase 2Efficacy & side effects
8(26.7%)
Phase 3Large-scale testing
4(13.3%)
Phase 4Post-market surveillance
14(46.7%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

75.9%

22 of 29 finished

Non-Completion Rate

24.1%

7 ended early

Currently Active

0

trials recruiting

Total Trials

32

all time

Status Distribution
Completed(22)
Terminated(7)
Other(3)

Detailed Status

Completed22
Terminated6
unknown3
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
32
Active
0
Success Rate
78.6%
Most Advanced
Phase 4

Trials by Phase

Phase 14 (13.3%)
Phase 28 (26.7%)
Phase 34 (13.3%)
Phase 414 (46.7%)

Trials by Status

terminated619%
completed2269%
unknown39%
withdrawn13%

Recent Activity

0 active trials
Showing 5 of 32
withdrawnphase_2

Efficacy and Safety of Rasagiline in Prodromal Parkinson's Disease

NCT05611372
completed

Rasagiline Tablets Special Drug Use-Results Survey "Survey on Long-term Safety"

NCT03727139
completedphase_2

Image Parkinson's Disease Progression Study

NCT02789020
completed

Effect of 2.5 Years of Rasagiline Therapy on Progression of Cognitive Biomarkers Assessed by MRI in Parkinson's Disease.

NCT02278588
completedphase_4

Parallel-Group Study to Assess the Effect of Rasagiline on Cognition in Patients With Parkinson's Disease

NCT01723228
View all 32 trials

Clinical Trials (32)

Showing 20 of 32 trialsScroll for more
NCT05611372Phase 2

Efficacy and Safety of Rasagiline in Prodromal Parkinson's Disease

Withdrawn
NCT03727139

Rasagiline Tablets Special Drug Use-Results Survey "Survey on Long-term Safety"

Completed
NCT02789020Phase 2

Image Parkinson's Disease Progression Study

Completed
NCT02278588

Effect of 2.5 Years of Rasagiline Therapy on Progression of Cognitive Biomarkers Assessed by MRI in Parkinson's Disease.

Completed
NCT01723228Phase 4

Parallel-Group Study to Assess the Effect of Rasagiline on Cognition in Patients With Parkinson's Disease

Completed
NCT01055379Phase 4

Rasagiline in Cognitive-impairment Related Depression: AzileCt in COgnitive-impairment Related DepressiOn

Completed
NCT02359552Phase 2

Rasagiline Rescue in Alzheimer's Disease Clinical Trial

Completed
NCT01786603Phase 2

Rasagiline in Subjects With Amyotrophic Lateral Sclerosis (ALS)

Completed
NCT02068625Phase 4

Rasagiline (Azilect) - Neuroprotection for Macula-off Retinal Detachment

Terminated
NCT01215227Phase 3

An Active-Controlled Extension Study to NCT01155466 [P04938] and NCT01227265 [P07037] (P06153)

Terminated
NCT01232738Phase 2

Trial of Safety and Efficacy of Rasagiline in Patients With Amyotrophic Lateral Sclerosis (ALS)

Completed
NCT01879241Phase 2

Study of Rasagiline in Patients With Amyotrophic Lateral Sclerosis

Completed
NCT01049984Phase 4

Rasagiline as Add on to Dopamine Agonists in the Treatment of Parkinson's Disease

Completed
NCT01442610Phase 4

Effects of Rasagiline on Sleep Disturbances in Parkinson's Disease

Completed
NCT01497652Phase 4

A Double Blind Placebo Controlled Trial Evaluating Rasagiline Effects on Cognition in Parkinson's Disease Patients With Mild Cognitive Impairment Receiving Dopaminergic Therapy

Completed
NCT01532128Phase 1

Effect of BIA 9-1067 on Rasagiline Pharmacokinetics

Completed
NCT01532141Phase 1

Effect of Rasagiline on BIA 9-1067 Pharmacokinetics

Completed
NCT00755027Phase 4

Rasagiline and Apathy in Parkinson's Disease

Completed
NCT01382342Phase 4

The Effect of Rasagiline on Cognition in Parkinson's Disease

Completed
NCT01556165Phase 3

Rasagiline in Early Parkinson's Disease Patients Not Treated With Levodopa in China

Completed

Drug Details

Intervention Type
DRUG
Total Trials
32